论文信息 - The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia-Related Bleeding. - 字舞流文

The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia-Related Bleeding.

[1] J. Harlé,et al. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients , 2017, PloS one.

[2] F. Durand,et al. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious , 2015, Medicine.

[3] D. Ross,et al. Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia , 2014, Allergy & rhinology.

[4] A. Alexopoulou,et al. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia , 2013, Expert opinion on biological therapy.

[5] J. Saurin,et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. , 2012, JAMA.

[6] C. Merlo,et al. An epistaxis severity score for hereditary hemorrhagic telangiectasia , 2010, The Laryngoscope.

[7] J. Gossage,et al. Evaluation of patients with hereditary hemorrhagic telangiectasia with video capsule endoscopy: a single-center prospective study. , 2007, Endoscopy.

[8] W. Fischbach,et al. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab , 2006, Annals of Hematology.